Skip to main content
S&P 5007,631.04-0.42%DOW52,277.84-1.12%NASDAQ25,981.13-0.11%BTC$81,431.00+0.17%ETH$2,401.40+0.80%GOLD$4,010.60-1.23%OIL$103.41+3.96%
Smart Investors Daily
SID Premium
DR

NASDAQ · DRIO

DarioHealth Corp.

Healthcare · Medical - Diagnostics & Research

$3.41

Up+$0.15 (+4.40%)

Updated Oct 23, 2026, 7:00 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
86.71M
P/E ratio
-51.67
Dividend yield
0.00%
52-week range
$3.13 – $16.50
Volume
198.42K
Avg. volume
68.53K

Price performance · DRIO

DRIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 22, 2026

DRIO closed at $3.41 after 21 trading sessions, down 49.63% for the selected period.

Last close
$3.41
Period change
-49.63%
Period low
$3.41
Period high
$6.77
Daily close
View OHLC price history
DRIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 22, 2026$3.60$3.6701$3.01$3.41198.42K
Oct 21, 2026$4.10$4.20$3.125$3.68266.18K
Oct 20, 2026$4.4897$4.62$3.85$4.08132.92K
Oct 19, 2026$4.82$5.3154$4.49$4.4931.03K
Oct 16, 2026$5.30$5.40$4.82$4.8226.69K
Oct 15, 2026$5.45$5.45$5.025$5.1310.33K
Oct 14, 2026$5.49$5.81$5.13$5.456.69K
Oct 13, 2026$5.18$5.54$5.18$5.549.07K
Oct 12, 2026$6.36$6.365$5.325$5.4211.3K
Oct 9, 2026$5.37$5.85$5.37$5.802.62K
Oct 8, 2026$6.02$6.05$5.43$5.4338.72K
Oct 7, 2026$5.93$6.29$5.93$6.082.61K
Oct 6, 2026$5.80$6.205$5.80$6.027.75K
Oct 5, 2026$6.53$6.54$5.80$5.8026.14K
Oct 2, 2026$6.17$6.605$6.07$6.4634.36K
Oct 1, 2026$6.6747$6.825$6.05$6.1656.07K
Sep 30, 2026$6.76$6.9131$6.62$6.629.25K
Sep 29, 2026$6.70$6.7897$6.61$6.623.57K
Sep 28, 2026$6.61$6.79$6.61$6.718.1K
Sep 25, 2026$6.77$6.82$6.61$6.6312.71K
Sep 24, 2026$6.71$6.77$6.66$6.778.99K

Latest DRIO news

The latest Smart Investors Daily articles mentioning DRIO.

Stock researchCompany · Overview

DRIO research

Overview

Company profile and research snapshot.

Company profile

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$16.00
Implied upside
—
Analysts
—
DRIO recent ratings
DateFirmRatingTarget
Aug 19, 2026Alliance Global PartnersBuy—
Aug 12, 2026TD CowenHold—
Mar 20, 2026StifelBuy—
May 19, 2025Litchfield HillsBuy—
Mar 11, 2025StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 6, 2026

DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the results of a review titled "An Independent Review of Evidence Supporting DarioHealth's Clinical and Cost-Savings Impact" conducted by the Managed Care Services Team of Aon plc ("Aon"), a leading global professional services firm.

Yahoo · Sep 17, 2026

Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5 million covered lives. The agreement was secured through Dario's strategic channel partnership with Amwell and is expected to launch and begin generating revenue in the first quarter of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By